Anti-Viral

FAVIPIRAVIR (BDFAVI) Tablet

$140.00

Favipiravir BDFAVI 200/400/800 Tablet represents a significant advancement in the management of viral infections, offering a targeted and effective therapeutic option to combat respiratory illnesses and emerging viral threats. By inhibiting viral replication and transmission, Favipiravir plays a crucial role in reducing the burden of disease and mitigating the impact of pandemics

Strength	Choose an option200mg400mg800mg
	Clear

Quantity

FAVIPIRAVIR (BDFAVI) Tablet quantity

Add to cart

Sku:

N/A

Tag:

FAVIPIRAVIR BDFAVI

Description

Favipiravir (BDFavi) Tablet is a broad-spectrum antiviral medication used in the treatment of certain viral infections. Favipiravir, the active ingredient in this medication, works by selectively inhibiting the RNA-dependent RNA polymerase enzyme, which is essential for the replication of RNA viruses. This inhibition prevents the viruses from multiplying, thereby reducing the severity and duration of symptoms associated with the viral infection.

Key Features:

• Antiviral Agent: Favipiravir (BDFavi) Tablet is an antiviral medication that acts against RNA viruses by inhibiting their replication. It has demonstrated activity against a wide range of RNA viruses, including influenza viruses, Ebola virus, and certain coronaviruses.
• Treatment of Viral Infections: Favipiravir is indicated for the treatment of viral infections such as influenza, COVID-19 (caused by SARS-CoV-2), and other emerging viral diseases. It is particularly useful in the management of viral infections that are associated with high morbidity and mortality rates.
• Oral Administration: Favipiravir (BDFavi) Tablet is administered orally, typically in the form of tablets, with or without food. The convenient dosing regimen enhances patient compliance and adherence to treatment.
• Efficacy: Clinical studies and real-world experience have demonstrated the efficacy of favipiravir in reducing viral load, shortening the duration of symptoms, and improving clinical outcomes in patients with viral infections. It is considered an important therapeutic option in the management of certain viral outbreaks and epidemics.
• Safety Profile: Favipiravir generally has a good safety profile when used as directed. However, like all medications, it may be associated with certain side effects, including gastrointestinal disturbances, elevated liver enzymes, and teratogenic effects. Patients should be closely monitored for adverse reactions during treatment.
• Patient Education: Patients prescribed Favipiravir (BDFavi) Tablet should receive comprehensive education regarding proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated about infection control measures to prevent the spread of the virus to others.
• Consultation with Healthcare Provider: Treatment with Favipiravir (BDFavi) Tablet should be initiated and monitored by a qualified healthcare provider experienced in the management of viral infections. Close monitoring and regular follow-up are essential to ensure optimal therapeutic response and patient safety.
• Access and Affordability: Efforts should be made to ensure equitable access to Favipiravir (BDFavi) Tablet for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate any financial barriers to treatment. Access to effective antiviral medications is crucial for the management of viral outbreaks and epidemics.

Additional information